Acknowledgment of Financial Commercial Support
No financial commercial support was received for this educational activity.
Acknowledgment of In-Kind Commercial Support
No in-kind commercial support was received for this educational activity.
Learners must complete an evaluation form to receive a certificate of completion. Your chosen sessions must be attended in their entirety. You must attend the entire webinar as partial credit is not available. If you are seeking continuing education credit for a specialty not listed below, it is your responsibility to contact your licensing/certification board to determine course eligibility for your licensing/certification requirement.
Joint Accreditation Statement
In support of improving patient care, this activity has been planned and implemented by Amedco LLC and Total Health Conferences. Amedco LLC is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
Amedco Joint Accreditation Provider Number: 4008163
ACCME Credit Designation Statement
Amedco LLC designates this live activity for a maximum of 2.00 AMA PRA Category 1 CreditsTM for physicians. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
ACPE Credit Designation Statement
Amedco LLC designates this activity for a maximum of 2.00 knowledge-based CPE contact hours. UAN: JA4008163-9999-23-155-L01-P | JA4008163-9999-23-155-L01-T
NOTE to Pharmacists: The only official Statement of Credit is the one you pull from CPE Monitor. You must request your certificate within 30 days of your participation in the activity to meet the deadline for submission to CPE Monitor.
ANCC Credit Designation Statement
Amedco LLC designates this activity for a maximum of 2.00 ANCC contact hours.
Objectives - After Attending This Program You Should Be Able To
1. Employ an understanding of personalized medicine to individualize the use of available drugs for lung cancers, gastrointestinal cancers, breast cancers, genitourinary cancers, and hematological malignancies. Communicate the efficacy and safety of the drugs discussed in the case studies and other emerging treatments for lung cancers, gastrointestinal cancers, breast cancers, genitourinary cancers, and hematological malignancies.
2. Understand the emerging and standard diagnostic tests used to assist in planning therapy for lung cancers, gastrointestinal cancers, breast cancers, genitourinary cancers, and hematological malignancies. Formulate management strategies, considering the contributory roles of local and systemic therapy.
3. Recall the design of ongoing clinical trials evaluating novel investigational agents and counsel appropriately selected patients about availability and participation.
Disclosure of Conflict of Interest
The following table of disclosure information is provided to learners and contains the relevant financial relationships that each individual in a position to control the content disclosed to Amedco. All of these relationships were treated as a conflict of interest, and have been resolved. (C7 SCS 6.1-6.2, 6.5)
All individuals in a position to control the content of CE are listed in the program book. If their name is not listed below, they disclosed that they had no financial relationships with a commercial interest.